This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Nivolumab (Opdivo) in combination with platinum

< Back

Nivolumab (Opdivo) in combination with platinum


Cancer and Palliative Care

October 2017

Nivolumab is an intravenous drug under development for the management of advanced (Stage IV) NSCLC. The drug acts on specific proteins (receptors) on immune cells, allowing the defence system of the body to decrease the growth of cancer cells. If licensed, Nivolumab in combination with the current standard of care (platinum doublet chemotherapy) may offer an additional treatment option for patients with advanced NSCLC who currently have failed to respond to standard of care chemotherapy alone.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Opdivo with platinum double chemotherapy for NSCLC


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts